Volume 10, Issue 7

New and Emerging Options for HIV Pre-exposure Prophylaxis (PrEP) May Increase Adherence and Reduce HIV Transmission

In this issue:

In this issue of eHIV Review, Matthew Spinelli, MD, MAS, Associate Professor of HIV, Infectious Disease, and Global Medicine at Zuckerberg San Francisco General Hospital, discusses the evidence for new and emerging options for HIV pre-exposure prophylaxis (PrEP). These expanded options include long-acting cabotegravir, twice-yearly lenacapavir, and the investigational oral agent MK-8527. Clinicians need greater awareness of emerging evidence for PrEP options as they become available, and the importance of choice in improving PrEP adherence.  

Learning objective:

 Assess efficacy, safety, and potential indications for new and emerging PrEP options.  

Author:

Matthew Spinelli, MD, MAS
Matthew Spinelli, MD, MAS

Associate Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, CA
(he/him/his)


Program Directors:

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA
(he/him/his)

Matthew Spinelli, MD, MAS

Associate Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, CA
(he/him/his)

Ethel D. Weld, MD, PhD

Associate Professor of Medicine, Physiology, Pharmacology & Therapeutics
Johns Hopkins School of Medicine
Baltimore, MD
(she/her/hers)

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: January 15, 2026
Expiration date: January 14, 2028